Harnessing Tumor Cell‐Derived Exosomes for Immune Rejection Management in Corneal Transplantation
Advanced Science · 2025
DOI: 10.1002/advs.202409207 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Jieru Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, China. Hauptthemen laut MEDLINE: Exosomes, Graft Rejection, Corneal Transplantation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Research Ward Excellence Program, National Natural Science Foundation of China, Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
Transplantation remains the definitive treatment for end‐stage organ failures, but its efficacy is frequently compromised by immune rejection. This study introduces a novel strategy by utilizing tumor‐derived exosomes from B16‐F10 melanoma cells (B16‐Exo), diverging from the conventional use of immune cell‐derived exosomes, to alleviate post‐transplantation immune rejection. Utilizing murine corneal transplantation as a model, it is demonstrated that B16‐Exo significantly reduces immune rejection, evidenced by decreased corneal opacity, neovascularization, and immune dysregulation, while enhancing postoperative survival. Proteomic analyses reveal differential expression of pivotal proteins in B16‐Exo, notably the JAK2 protein within the JAK‐STAT signaling pathway, which has been mechanistically demonstrated to amplify the activity of myeloid‐derived suppressor cells (MDSCs) and inhibit T cell proliferation. These findings demonstrate the significant immunomodulatory effect of B16‐Exo in transplant immunology, supporting the continued exploration of tumor‐derived exosomes as a platform to uncover novel immunosuppressive mechanisms in transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, China.
- Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology & Visual Sciences, Beijing, 100730, China.
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
- Key Laboratory of Biological Nanotechnology of National Health Commission, Changsha, Hunan, 410008, China.
ORCID-Profile: Jieru Yang, Wenhu Zhou
Förderung
- Beijing Research Ward Excellence Program
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
- Research Foundation of Education Bureau of Hunan Province, China
- Association of Physician Associates in Obstetrics and Gynecology
Zitieren
APA
Yang, J., Kang, H., Liu, Y., Lu, S., Wu, H., Zhang, B., He, Y., & Zhou, W. (2025). Harnessing Tumor Cell‐Derived Exosomes for Immune Rejection Management in Corneal Transplantation. Advanced Science. https://doi.org/10.1002/advs.202409207
Vancouver
Yang J, Kang H, Liu Y, Lu S, Wu H, Zhang B, et al. Harnessing Tumor Cell‐Derived Exosomes for Immune Rejection Management in Corneal Transplantation. Advanced Science. 2025. doi:10.1002/advs.202409207
BibTeX
@article{Yang2025,
author = {Yang, Jieru and Kang, Huanmin and Liu, Yingyi and Lu, Shan and Wu, Huihui and Zhang, Bikui and He, Yan and Zhou, Wenhu},
title = {Harnessing Tumor Cell‐Derived Exosomes for Immune Rejection Management in Corneal Transplantation},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202409207}
}
EUVIMED